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Cervical	 cancer	 is	 an	 important	 public	 health	
problem.	It	is	the	second	most	common	malignancy	
among	women	worldwide	 and	 the	 first	 in	many	
developing	countries,	including	Korea	[1].	It	is	widely	
accepted	that	high-risk	type	human	pappillomavirus	
(HPV)	 infection	 is	an	obligatory	 factor	 in	malignant	
transformation	within	the	epithelial	cells	of	the	uterine	
cervix	[2].	However,	HPV	infection	alone	is	insufficient	
to	 cause	 invasive	 cervical	 cancer	 [3].	 The	 role	of	
promoting	cofactors	in	the	later	stages	of	progression	
into	cervical	malignancy	remains	uncertain.	Possible	
candidates	are	the	cyclin	proteins	that	are	cyclically	
synthesized	and	destroyed	during	the	cell	cycle.
There	are	many	well-known	cyclins,	 including	11	
major	classes	and	some	subclasses,	labeled	A,	B1-2,	
C,	D1-3,	E1-2,	F,	G1-2,	H,	I,	K,	T1-2	to	H.	They	share	a	
conserved	amino	acid	region,	known	as	the	cyclin	box,	
through	which	they	interact	with	their	cyclin	dependent	
kinases	(cdks)	[4,	5].		Cyclins	are	also	grouped	accord-
ing	to	their	phase	of	activity.	The	G1	cyclins	include	D1	
and	E,	which	are	active	in	the	G1	phase	and	regulate	the	
G1–S	phase	transition.	Cyclin	A	is	active	in	the	S	and	
late	G2	phase,	while	B1-2	are	active	in	the	G2	phase	and	
regulate	mitosis.	Cell	cycle	dysregulation	is	a	feature	of	
all	human	cancers	and	there	is	evidence	suggesting	a	
role	for	cyclins	in	human	cancer	[6].
The	human	B-type	class	of	cyclins	consists	of	three	
closely	related	members,	cyclins	B1,	B2,	and	B3,	which	
control	the	G2-M	transition	through	interaction	with	the	
cdk1	protein	kinase.
Cyclin	B1	was	the	first	human	cyclin	identified	and	
is	the	best	characterized	among	the	three	members	
[7].	Cyclin	B1	complexes	solely	with	cdk1	(cdc2)	to	
form	 the	mitosis-promoting	 factor,	which	 regulates	
the	G2–M	transition	and	 is	 the	primary	 regulator	of	
mitosis.	The	mitosis-promoting	 factor	 is	 located	 in	
the	cytoplasm	late	in	the	S	phase,	but	relocates	to	the	
nucleus	shortly	before	the	envelope	breakdown.	P53	
was	recently	shown	to	prevent	the	G2–M	transition	by	
decreasing	cyclin	B	levels	and	attenuating	activity	of	
the	cyclin	B	promoter	[5,	8,	9].
The	cyclin	D1	protein	is	a	major	positive	regulator	
of	the	progression	from	the	G1	to	S	phase.There	is	a	
homeostatic	 feedback	 loop	between	cyclin	D1,	Rb,	
and	p27Kip1	[5,10].		Cyclin	D1	is	often	found	disrupted	
in	 the	cancer	cell	genome	by	chromosome	11q13	
translocation	or	gene	amplification.	Approximately	
50%	of	mammary	carcinomas	have	been	shown	 to	
overexpress	the	cyclin	D1	protein.	Molecular	aberra-
tions	accounting	for	increased	mRNA	transcripts	of	cy-
clin	D1	in	other	cancers	include	gene	rearrangements	
and	amplification.	Amplification	has	been	implicated	
in	many	tumors,	including	bladder	and	ovarian	cancer	
[11].	 In	contrast,	our	previous	study	suggested	that	
there	is	no	correlation	between	gene	alterations	and	
protein	D1	in	cervical	squamous	cell	cancer	[12].	
Previously,	we	studied	a	large	collection	of	fresh	or	
paraffin-embedded	samples	from	patients	with	cervical	
cancer	to	analyze	the	expression	levels	of	cyclin	D1,	E,	
A	by	reverse	transcription	polymerase	chain	reaction	
(RT-PCR)	and	immunohistochemical	staining	methods	
[12–14].	We	found	that	RT-PCR	or	immunohistochemical	
assay	could	detect	the	cyclins	message	in	nearly	all	the	
cervical	cancer	specimens.	However,	 these	methods	
lacked	specificity	and	only	yielded	a	semi-quantitative	
result.	Gene	expression	analysis	 requires	sensitive,	
precise,	and	reproducible	measurement.	Hence,	we	
reported	 the	development	of	a	quantitative	real-time	
RT-PCR	assay	 for	cyclin	B1	and	D1	expression	with	
high	sensitivity	and	specificity	for	cervical	cancer.	Our	
objective	was	to	perform	a	quantitative	real-time	RT-PCR	
assay	in	normal	and	cervical	cancer	tissues	to	evaluate	
the	expression	level	and	status	of	cyclin	B1	and	D1.	
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matErials and mEthods
Patients. Fresh	 cervical	 tissue	 samples	were	
obtained	from	51	patients	treated	at Yonsei Medical	
Center.	These	included	41	invasive	cervical	cancers	
and	10	normal	cervix	tissues	that	served	as	the	con-
trol.	Of	the	41	patients	with	cervical	cancer,	9	cases	
were	stage	I,	27	cases	were	stage	II,	and	5	cases	were	
stage	III.	Dissected	tissue	samples	were	immediately	
frozen	and	stored	in	liquid	nitrogen.	The	patients’	ages	
ranged	from	29	to	80	years	with	a	mean	of	53.08	years.	
Regarding	distribution	according	 to	stage,	patients	
with	stage	II	cervical	carcinoma	were	the	most	numer-
ous.	According	to	cell	type,	37	contained	squamous	
cells	and	4	were	adenocarcinomas.	The	HPV	infection	
was	detected	in	41	cervical	carcinoma	tissues,	and	the	
HPV	types	included	types	4,	11,	14,	16,	18,	33,	35,	45,	
58,	63,	69	and	others.	
RNA isolation and cDNA preparation. For	
RNA	preparation,	samples	were	disrupted	into	small	
pieces	and	RNA	was	 isolated	 from	 the	 tumor	and	
control	samples	using	SV	total	RNA	isolation	system	
(Promega).	A	total	of	1	µg	RNA	of	each	sample	was	
reverse	 transcribed	using	an	oligo	d(T)	primer	and	
RNase	H-	MMLV	reverse	transcriptase,	according	to	
the	manufacturer’s	protocol	(Fermentas).	The	reverse	
transcription	reaction	contained	the	following	in	a	50	µl	
volume:	200	units	MMLV	enzyme,	1×	MMLV	buffer,	
20	units	Rnasin,	 0.5	 µg	 oligo	d(T),	 2.5	mM	dNTP	
mix,	and	DNase	treated	total	RNA.	The	reaction	was	
incubated	at	70	°C	 for	10	min.	The	control	and	 ref-
erence	RNA′s	were	 reverse-transcribed	alongside	
patient	RNA	 for	each	 run.	The	cDNA	was	stored	at	
–20	°C	and	was	used	 for	 each	PCR	 reaction.	 The	
quality	of	 the	cDNA	was	confirmed	by	amplification	
of	 glyceraldehyde–3–phosphate-dehydrogenase	
(GAPDH)	and	only	samples	with	consistent	and	strong	
amplifications	were	included	in	the	final	analyses.	
Analyses of gene expression by real-time 
quantitative RT-PCR. The	quantitation	of	mRNA	levels	
was	carried	out	using	a	real-time	fluorescence	detection	
method.	The	cDNA	was	prepared	as	described	above	
and	amplified	by	PCR	in	the	ABI	prism	7700	sequence	
detector	(PE	Biosystems,	USA).	The	reaction	mixture	
for	cyclin	B1/D1	contains	the	following	in	a	final	volume	
of	50	µl:	25	µl	Taqman	mix,	2.5	µl	cyclin	B1	or	D1	primer	
mix,	1	µg	cDNA,	and	added	 free-water	 to	50	µl.	The	
quantitative	real-time	PCR	was	performed	as	follows:	an	
initial	cycle	for	10	min	at	95	°C,	followed	by	50	bi-phasic	
cycles	of	15	s	at		95	°C,	and	1	min	at	60	°C.
The	primer	and	probe	sequences	were	published	
previously	 (Table	1)	 [15,	16].	All	primer	and	probe	
combinations	were	positioned	to	span	an	exon-exon	
junction.	The	probes	were	labeled	at	the	5′	end	with	a	
FAM	(6-carboxyfluorescein)	probe	and	at	the	3′	end	
with	TAMRA	(6-carboxytetramethylrhodamine),	which	
served	as	a	quencher.	Initial	template	concentration	
was	 calculated	 from	 the	 cycle	 number	when	 the	
amount	of	PCR	product	passed	a	threshold	set	in	the	
exponential	phase	of	the	PCR	reaction.	
Table 1. The sequences of primer and probe of cyclin B1 and D1
Cyclin B1 :
Forward primer: 5′—CTC CTG TCT GGT GGG AGGA—3′
Reverse primer: 5′—CTG ATC CAG AAT AAC ACC TGA—3′
Probe: 5′—FAM-AGA GTG GAG TTG TGC TGG CT-TAMRA—3′
Cyclin D1 :
Forward primer: 5′—CTG GCC ATG AAC TAC GTG GA—3′
Forward primer: 5′—GTC ACA CTT GAT CAC TCT GG—3′ 
Probe: 5′—FAM-AGA AGC GTG TGA GGC GGT AGT AGG A-TAMRA—3′
GAPDH :
Forward primer: 5′—GAA GGT GAA GGT GGG AGT C—3′
Forward primer: 5′—GAA GAT GGT GAT GGG ATT TC—3′
Probe: 5′—FAM-CAA GGT TCC CGT TCT CAG CC-TAMRA—3′
The	 threshold	 cycles	 (Ct)	 were	 recorded	 for	
the	 target	gene	and	 reference	 in	 all	 the	 samples.	
The	 results	were	calculated	 relative	 to	a	 reference	
standard,	called	a	calibrator.	The	results	of	the	real-
time	PCR	were	calculated	by	“Comparative	Ct	method	
of	Quantitation”	 (ΔΔCt)	 [17,	18].	This	method	was	
outlined	in	the	ABI	Prism	Sequence	Detection	System	
User	Bulletin	from	the	following	formulas:
ΔCt	(sample)	=	Ct	(target	gene)	–	Ct	(GADPH),
ΔΔCt	=	ΔCt	(tumor)	–	ΔCt	(control)
Relative	expression	=	2-ΔΔCt
The	three	targets	were	analyzed	separately.	Then,	
cyclin	B1	and	D1	were	each	normalized	to	GADPH	as	an	
internal	standard.	Final	relative	cyclin	B1/D1	expression	
levels	of	 each	unknown	sample	were	obtained	by	
division	of	cyclin	B1/D1	copy	numbers	by	GADPH	copy	
numbers.	The	normalization	accounts	for	variability	in	
the	samples’	reverse	transcription	efficiency	and	RNA	
quantity	and	quality.	The	ΔΔCt	was	calculated	separately	
for	cyclin	B1	and	cyclin	D1,	for	each	sample,	using	the	
cell	line	HeLa	as	the	calibrator.	HeLa	was	chosen	as	the	
reference	calibrator	because	it	expressed	high	levels	of	
cyclin	B1	or	cyclin	D1,	and	it	is	potentially	a	consistent	
source	of	calibrator	template.	At	least	two	independent	
analyses	were	performed	for	each	sample	and	each	
gene.	Analyses	of	 the	gene	expression	data	were	
performed	without	knowledge	of	the	patients′	data.
Real-time PCR efficiency assay. To	use	 the	
2-ΔΔCt	calculation,	 the	PCR	efficiencies	of	 the	 target	
and	 control	 assays	 need	 to	 be	 similar	 [17].	The	
relative	efficiencies	were	measured	by	 varying	 the	
input	amount	of	RNA,	measuring	the	Ct	values,	and	
calculating	 the	ΔCt	 values	 for	 the	 various	assays.	
Graphing	 the	ΔCt	values	 relative	 to	 input	 total	RNA	
should	give	a	line	with	a	slope	<	0.1.	The	range	of	input	
RNA	should	be	from	10	ng	to	1000	ng.	
Western blot analysis of cyclin B1 and D1. The	
cervical	tissues	were	all	homogenized	and	then	lysed	
with	cell	lysis	buffer	(Cell	Signaling	Technology,	Inc),	
according	to	the	manufacturer	protocol.	After	incuba-
tion	on	ice	for	10	min,	tissue	lysates	were	clarified	by	
centrifugation	at	13,000	rpm	for	five	min	and	protein	
concentration	of	 the	supernatants	was	determined	
with	 a	Bio-Rad	DC	protein	 assay	 (Bio-Rad,	USA).	
40	µg	of	 total	protein	was	 loaded	 in	each	 lane.	The	
samples	were	subjected	to	8–10%	SDS-PAGE.	The	
resolved	proteins	were	blotted	to	a	PVDF	membrane,	
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which	were	then	blocked	at	overnight	4	°C	in	TBS	buf-
fer	(20	mM	Tris	base,	137	mM	sodium	chloride,	1	M	
hydrochloric	acid,	pH	7.6)	containing	5%	non	fat	milk.	
The	membrane	was	then	incubated	with	the	primary	
antibodies:	mouse-anti	 cyclinB1	 (clone	V152,	Cell	
Signaling	 Technology,	 Inc),	 anti-human	 cyclinD1	
(clone	Dcs6,	Cell	 Signaling	Technology,	 Inc)	 and	
mouse-anti	GADPH	(Cell	Signaling	Technology,	Inc)	
for	1	h	at	 room	 temperature.	The	concentration	of	
each	antibody	was	used	as	suggested	by	the	suppli-
ers.	Peroxidase	labeled	anti-mouse	antibodies	were	
used	as	a	secondary	antibody,	diluted	in	TBS	with	5%	
(w/v)	milk,	and	developed	using	the	chemiluminescent	
ECL	kit	and	Hyperfilm	ECL	(Amersham	Biosciences,	
USA).	Quantification	of	proteins	was	performed	by	
using	a	laser	densitometer	and	analysis	software	(IM-
AGE	READER	LAS-1000	lite,	Fuji	Photo	Film	Co.,	Ltd.,	
Japan),	while	referring	to	the	standard	series.	The	den-
sitometric	integral	derived	from	each	sample	band,	i.e.	
the	integral	of	a	mean	density	over	a	measured	area,	
was	 taken	 to	calculate	 the	amount	 in	each	sample,	
according	to	the	known	standard	values.	
Statistical analyses. Data	were	analyzed	using	
parametric	and	nonparametric	statistics,	SPSS	11.0	
(Chicago,	USA).	Descriptive	statistics	were	used	for	
quantitative	experimental	data	and	are	summarized	as	
means	and	standard	deviations.	Continuous	variables	
were	examined	for	a	normal	distribution	(Kolmogorov-
Smirnov	test)	before	adopting	parametric	statistics.	
Differences	 between	 continuous	 variables	were	
evaluated	by	an	independent-sample	T	test.	One	way	
ANOVA	and	logistic	regression	analysis	were	done	for	
normally	distributed	variables.	The	Mann-Whitney	U	
test	and	the	Kruskal-Wallis	test	were	done	for	variables	
that	were	not	normally	distributed.	Differences	were	
considered	significant	when	 the	probability	of	error	
was	below	5%	(P <	0.05).
rEsults
Analysis of cyclin expression in normal and 
cervical cancer tissues with real-time RT-PCR. 
To	determine	cyclin	B1	and	D1	transcript	level	in	fresh	
human	cervical	carcinoma	tissues,	we	used	a	real-time	
quantitative	RT-PCR	assay	based	on	TaqMan	method-
ology.	GAPDH	mRNA	was	measured,	as	a	reference,	
to	normalize	cyclin	B1	and	D1	mRNA	levels.	Primers	
and	probes	were	selected	to	avoid	amplification	from	
genomic	DNA	and	target	sequences	were	kept	small	
to	ensure	 the	detection	of	 fragmented	and	partially	
degraded	RNA.	The	PCR	efficiencies	of	 the	 target	
and	control	 assays	were	performed.	The	slope	 for	
cyclin	B1	was	0.088	and	the	slope	for	cyclin	D1	was	
0.094,	relative	to	GAPDH	for	the	range	of	input	cDNA	
of	10–1000	ng.
In	the	study,	we	compared	cyclin	B1	and	D1	expres-
sion	in	cervical	cancer	and	normal	tissues.	These	anal-
yses	revealed	that	cyclin	B1	transcripts	had	a	higher	
expression	in	cervical	cancer	(P =	0.019)	and	there	was	
a	decreased	trend	from	stage	I	(0.76	±	0.68)	to	stage	
III	 (0.23	±	0.39)	 in	cervical	cancer	cases	 (Table	2).	
Although	we	found	a	high	level	of	cyclin	D1	expression	
in	some	cervical	cancer	cases,	no	significant	statistical	
differences	were	observed.	In	addition,	we	also	found	
an	increase	in	cyclin	D1	mRNA	expression	from	stage	I	
(2.17	±	2.33)	 to	 III	 (6.66	±	10.48)	 in	cervical	cancer	
cases.	Moreover,	no	significant	differences	in	terms	
of	cyclin	expression	were	found	between	the	different	
stages	of	cervical	carcinoma.
Table 2. Expression of cyclin B1 and D1 in the uterine cervix
Tissue Cyclin B1 Cyclin D1
2– ∆ ∆ Ct value (mean ± SD) 2– ∆ ∆ Ct value (mean ± SD) 
Control (n = 10)
Cervical cancer (n = 41)
Stage I (n = 9)
Stage II (n = 27)
Stage III (n = 5)
0.03 ± 0.05
0.59 ± 0.72a
0.76 ± 0.68
0.57 ± 0.76
0.23 ± 0.39
3.22 ± 2.29
3.29 ± 4.63
2.17 ± 2.33
3.24 ± 4.32
6.66 ± 10.48
aP = 0.019 (cervical cancer vs. control), Students t-test.
Western blotting of cyclin B1 and D1 in cervical 
carcinoma. The	mRNA	expression	level	of	cyclin	B1	
and	D1	were	analyzed	with	 real-time	RT-PCR.	We	
wanted	 to	directly	detect	cyclin	B1	and	D1	protein	
expression.	So,	we	 selected	29	cases	of	 cervical	
cancer	and	6	cases	of	normal	cervical	tissues	in	which	
mRNA	expression	was	analyzed	by	real-time	RT-PCR.	
In	western	blotting,	cyclin	B1	protein	was	detected	
as	a	60	KDa	and	cyclin	D1	protein	was	36	KDa	band	
(Figure).	Then,	we	compared	the	expression	levels	of	
mRNA	with	protein	expression	levels	of	cyclinB1	and	
D1	in	cervix	tissue	with	and	without	cervical	cancer.	
Our	study	revealed	a	statistically	significant	increase	
in	 expression	of	 cyclin	B1	 in	patient	with	 cervical	
compared	to	normal	cervix	tissue	(P =	0.031)	(Table	3).	
These	 results	agreed	with	 the	 results	of	 the	mRNA	
analysis	by	 real-time	PCR.	There	was	no	statistical	
difference	in	expression	of	cyclin	D1	between	cervical	
cancer	and	normal	tissues,	and	no	correlation	between	
the	expression	of	mRNA	and	protein.
Table 3. The protein analysis of cyclin B1and D1 by Western blot
Tissue Cyclin B1 (mean ± SD) Cyclin D1 (mean ± SD)
Control
Cervical cancer
0.21 ± 0.11
0.33 ± 0.11a
0.27 ± 0.16
0.32 ± 0.20
aP = 0.031 (cancer vs. control), Students t-test.
disCussion 
Exact	quantification	of	cyclin	B1/D1	expression	
levels	might	elucidate	the	causes	and	consequences	
of	cyclin	B1	or	D1	deregulation	in	cervical	cancer.	The	
quantitative	real-time	RT-PCR	assay	described	in	this	
report	 represents	a	major	 improvement	over	other	
assays	designed	to	quantify	cyclin	B1/D1	expression	
in	tissue	specimens.	This	assay	can	detect	the	PCR	
product	following	each	cycle	of	the	reaction,	during	
the	linear	range	of	amplification,	then	eliminates	the	
need	for	post	PCR	analysis.	Real-time	RT-PCR	assay	
is	an	ideal	tool	for	the	detection	and	quantification	of	
cyclins	 in	cervical	carcinoma	because	 it	 is	 reliable,	
rapid,	sensitive,	and	specific.	Another	advantage	is	its	
applicability	to	the	degraded	nucleic	acids	obtained	
from	fixed	and	embedded	cervical	tissue	specimens,	
which	neither	Southern	nor	Northern	blotting	of	tissue	
RNA	can	be	performed	successfully	[17,	18].	In	brief,	
real-time	RT-PCR	combined	the	speed	and	ease	of	a	
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PCR-based	system	with	an	accurate	and	reproducible	
quantification	methodology	and	therefore	has	the	po-
tential	to	become	a	routine	diagnostic	tool.
figure. Western blot	of	cyclin	B1	and	D1	(a)	and	boxplot	graphs	
demonstrating	the	cyclin	B1	and	cyclin	D1	protein	expression	in	
normal	cervical	and	cervical	carcinoma	tissues.	(a):	Western	blot	
of	cyclin	B1	and	D1	in	normal	and	cancer	cervical	tissues. Protein	
extracts	were	separated	by	10%	SDS–PAGE,	transferred	from	
the	gel	to	PVDF	membranes,	and	immunoblotted	with	cyclin	B1	
and	D1	monoclonal	antibodies	(HeLa:	HeLa	cell	line;	C:	control	
tissue;	T1-4:	tumor	samples).	(b):	Boxplot	graphs	demonstrating	
cyclin	B1	and	cyclin	D1	protein	expression	in	normal	cervix	and	
cervical	carcinoma	(Western	blot).	The	lines	across	the	boxes	
represent	the	medians	and	the	whiskers	extend	to	the	highest	and	
lowest	values,	excluding	outliers.	The	small	circles	and	asterisks	
identify	outliers	and	extreme	values.
In	this	study,	results	were	calculated	by	the	by	com-
parative	Ct	method	of	quantification	(2-ΔΔCt	method).	
The	relative	expression	of	cyclin	and	GAPDH	genes	
could	be	estimated	 from	 the	difference	 in	Ct	 values	
(ΔCt).	The	ΔCt	value	would	be	normalized	to	a	control	
by	subtracting	the	ΔCt	value	obtained	with	the	calibrator	
to	yield	a	ΔΔCt.	Ct	values	for	cyclin	B1/D1	and	GAPDH	
in	the	test	tissues	were	compared	with	those	obtained	
with	the	HeLa	cell	line.	The	greater	the	ΔΔCt	value,	the	
lower	the	expression	of	cyclin	B1/D1	in	the	specimens.	
The	2-ΔΔCt	method	is	a	convenient	method	to	analyze	
the	relative	changes	in	gene	expression	from	real-time	
quantitative	RT-PCR	experiments.
The	main	purpose	of	this	study	was	to	evaluate	the	
potential	link	between	the	expression	of	cyclin	B1/D1	
and	cervical	tumorigenesis.	As	a	key	cell	cycle	modu-
lator	of	the	G2-M	transition,	cyclin	B1	is	considered	
to	play	an	 important	 role	 in	 various	human	 tumors.	
However,	to	the	best	of	our	knowledge,	this	is	the	first	
report	to	demonstrate	the	up-regulation	of	cyclin	B1	
expression	in	patients	with	cervical	carcinoma	using	
quantitative	real-time	RT-PCR	assay.	This	finding	was	
in	agreement	with	the	previously	published	study	by	
Kanai	et	al.	They	reported	elevated	cyclin	B1	levels	in	
invasive	carcinomas	and	concomitantly	elevated	levels	
of	cdk1	in	the	immunohistochemical	study	[19].		
On	the	other	hand,	no	significant	difference	 in	the	
expression	of	 cyclin	B1	was	 found	among	various	
clinicopathological	parameters	 including	histology,	
histological	subtype,	 tumor	 lesion,	and	patient’s	age.	
Furthermore,	we	found	that	there	was	a	trend	of	decrease	
in	the	mRNA	expression	of	cyclin	B1	with	each	advancing	
stage.	Other	studies	have	also	shown	that	in	high-grade	
cervical	precancerous	lesions,	cyclin	B1	expression	was	
up-regulated	and	persists	into	the	upper	epithelial	layers	
[4].	This	suggests	that	cyclin	B1	could	play	a	crucial	role	
in	the	early	phase	of	cervical	carcinogenesis.	
Because	 it	 is	 not	 clearly	understood,	 there	are	
controversial	results	on	the	role	of	cyclin	D1	in	cervi-
cal	carcinogenesis	and	clinical	outcome	[20,	21].	The	
hypophosphorylated	form	of	Rb,	complexed	with	E2F,	
serves	as	activator	of	cyclin	D1	transcription	by	binding	
to	its	promoter.	This	drives	cyclin	D1	in	the	early	and	mid	
G1	phase	of	the	cell	cycle.	Since	D	type	cyclins	and	HPV	
E7	possess	similar	binding	regions	for	pRb	and	pRb-
related	pocket	proteins,	inactivation	of	pRb	either	by	the	
cyclin/cdk	complexes	in	G1	or	by	interaction	with	the	
high-risk	HPV	oncoprotein	E7	may	result	in	a	decreased	
expression	of	cyclin	D1	[6,	22].	In	this	study,	we	found	
no	significant	difference	in	cyclin	D1	mRNA	expression	
between	cervical	cancer	and	normal	cervical	tissues.	
This	finding	was	slightly	different	from	previous	stud-
ies,	which	described	significantly	lower	in	HPV-positive	
cervical	lesions	compared	to	HPV-negative	cases	and	
normal	cervical	epithelium	[22].	Different	detection	
methods	and	analysis	standards	may	have	caused	the	
conflicting	observations	because	semi-quantitative	as-
says,	including	immunohistochemical	assay,	RT-PCR,	
and	Western	analysis,	were	used	to	detect	expression	
levels	of	cyclins	and	other	molecules	[23].	Further	study	
of	this	phenomenon	is	warranted.	
In	summary,	 this	study	demonstrated	 that	cyclin	
B1	mRNA	expression	was	significantly	 increased	 in	
invasive	cervical	carcinomas	compared	with	normal	
cervix.	This	change	may	play	a	 role	 in	uncontrolled	
proliferation	 and	malignant	 transformation	 of	 the	
uterine	cervix.	However,	additional	molecular	studies	
to	 identify	 the	amplification	of	 the	cyclin	B1	and	D1	
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genes	or	the	source	of	cyclin	protein	overaccumulation	
will	be	necessary	to	clarify	these	findings.
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особенности экспрессии циклинов B1 и d1  
при рАке шейки мАтки
Цель: циклины представляют собой семейство регуляторных белков, контролирующих клеточный цикл. Наличие 
функциональных и структурных нарушений регуляторов клеточного цикла (циклинов и циклинзависимых киназ) было 
отмечено в клетках различных злокачественных новообразований. Целью данного исследования было проведение 
количественного определения циклинов B1 и D1 в клетках рака шейки матки. Методы: определение уровня экспрессии 
циклинов B1/D1 (mRNA и белков соответственно) в свежеполученных клетках инвазивного рака шейки матки (n = 41) и 
нормальной ткани шейки матки (n = 10) проводили методами RT-PCR в режиме реального времени и Вестерн-блот анализа. 
Результаты: отмечен более высокий уровень экспрессии гена циклина В1 в клетках инвазивного рака шейки матки, чем в 
клетках нормальной ткани (P = 0,019). Не выявлены значительные различия в уровне  экспрессии гена циклина D1. При 
Вестерн-блот анализе получены аналогичные результаты. Выводы: результаты исследования подтверждают концепцию 
об активации экспрессии циклина В1 при раке шейки матки. Аберрантная экспрессия циклина В1 может играть важную 
роль при злокачественной трансформации эпителия шейки матки.
Ключевые слова: циклин В1, циклин D1, рак шейки матки, RT-PCR в режиме реального времени, Вестерн- блоттинг.
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